Drug intelligence / Profile preview

[99mTc]Tc-HYNIC-mAbLRRC15

Development stage
Unknown
Lead developer
Huazhong University of Science and Technology
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

[99mTc]Tc-HYNIC-mAbLRRC15 is a technetium-99m labeled monoclonal antibody targeting leucine-rich repeat-containing protein 15 (LRRC15). LRRC15 is highly overexpressed in cancer-associated fibroblasts (CAFs) within the tumor microenvironment of multiple solid malignancies, including pancreatic, breast, and colorectal cancers, while exhibiting minimal expression in most normal tissues. The radiotracer is designed for noninvasive evaluation of LRRC15 expression and accurate diagnosis of malignancies using SPECT/CT imaging. It has been evaluated in preclinical subcutaneous tumor-bearing mouse models and in a first-in-human clinical study in a patient with colorectal cancer.

Other names
99mTc-HYNIC-mAbLRRC15[99mTc]Tc-HYNIC-mAbLRRC15Tc-HYNIC-mAbLRRC15Tc-HYNIC-mAbLRRC-15Tc-HYNIC-mAbLRRC 15
02

Targets

LRRC15 (Leucine-rich repeat-containing protein 15)

Beyond the preview

Go deeper on [99mTc]Tc-HYNIC-mAbLRRC15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [99mTc]Tc-HYNIC-mAbLRRC15.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call